Atr-2 cell cycle checkpoint

Abstract

Polynucleotides encoding novel Atr-2 cell cycle checkpoint polypeptides are disclosed, along with expression constructs comprising the polynucleotides, host cells transformed with the expression constructs, methods to make the Atr-2 polypeptides using the host cells, Atr-2 polypeptides, and binding partners of the Atr-2 polypeptides.

1 - 19 . (canceled)  
     
     
         20 . A method to identify a binding partner compound of an Atr-2 polypeptide wherein said Atr-2 polypeptide is selected from the group consisting of: 
 a) a purified and isolated mature Atr-2 polypeptide comprising the amino acid sequence set out in SEQ ID NO: 2;    b) a purified and isolated mature Atr-2 polypeptide encoded by a polynucleotide comprising the sequence set out in SEQ ID NO: 1; and    c) a purified and isolated Atr-2 polypeptide with kinase activity encoded by a polynucleotide selected from the group consisting of:    i) the polynucleotide set out in SEQ ID NO: 1;    ii) a polynucleotide encoding a polypeptide encoded by the polynucleotide of (i); and    iii) a polynucleotides that hybridizes to the complement of the polynucleotide of (i) or (ii) under moderately stringent conditions,    said method comprising the steps of:    I) contacting the Atr-2 polypeptide with a compound under conditions which permit binding between the compound and the Atr-2 polypeptide; and    II) detecting binding of the compound to the Atr-2 polypeptide.    
     
     
         21 . The method according to  claim 20  wherein the binding partner modulates activity of the Atr-2 polypeptide.  
     
     
         22 . The method according to  claim 21  wherein the compound inhibits activity of the Atr-2 polypeptide.  
     
     
         23 . The method according to  claim 21  wherein the compound enhances activity of the Atr-2 polypeptide.  
     
     
         24 - 27 . (canceled)  
     
     
         28 . A compound identified by the method according to  claim 20 .  
     
     
         29 . A composition comprising the compound according to  claim 28  and a pharmaceutically acceptable carrier.